^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Myelodysplastic Syndrome
    Drug:Inqovi (decitabine/cedazuridine) (DNMT inhibitor, Cytidine deaminase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    07/07/2020
    Excerpt:
    INQOVI is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, indicated for treatment of adult patients with myelodysplastic syndromes (MDS)…
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Myelodysplastic Syndromes...Oral decitabine and cedazuridine (DEC-C) could be considered as substitution for intravenous decitabine...
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Astex Press Release
    Title:

    Astex Pharmaceuticals Presents Overall Survival Data From ASCERTAIN Phase 3 Study of Oral Hypomethylating Agent INQOVI® (decitabine and cedazuridine) in MDS and CMML at International Congress on Myelodysplastic Syndromes

    Published date:
    09/23/2021
    Excerpt:
    Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announced updated clinical data, including median overall survival (mOS), from the ASCERTAIN phase 3 trial of INQOVI®, the company’s orally administered fixed-dose combination of decitabine and cedazuridine (ASTX727 or DEC-C) in adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML). mOS was 31.7 months.
    Trial ID:
    Ascertain